ClearPoint Neuro (NASDAQ:CLPT) Issues Quarterly Earnings Results

ClearPoint Neuro (NASDAQ:CLPT) posted its quarterly earnings results on Wednesday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05), Zacks reports. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $8.23 million. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Price Performance

NASDAQ:CLPT traded down $2.35 during trading hours on Thursday, reaching $14.87. The company’s stock had a trading volume of 114,907 shares, compared to its average volume of 200,182. The company has a market cap of $410.19 million, a price-to-earnings ratio of -21.35 and a beta of 1.03. ClearPoint Neuro has a one year low of $5.11 and a one year high of $19.22. The business’s 50-day moving average is $16.67 and its 200-day moving average is $13.80.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Lake Street Capital boosted their price target on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. B. Riley boosted their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, January 28th.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.